Qingfeng Pharmaceutical

Executive Summary

Qingfeng Pharmaceutical is a privately held Chinese company established in 1998, specializing in the development and manufacture of small molecule pharmaceuticals. With 200-500 employees, the company focuses on creating generic and improved versions of existing drugs, as well as novel chemical entities. Its products serve both the domestic Chinese market and international partners, positioning it as a reliable player in the generic and specialty pharmaceutical space. The company's ability to navigate China's regulatory environment and cost-effective manufacturing underpins its competitive advantage. While operating in a highly competitive generic market, Qingfeng's diversification into novel chemical entities offers potential for higher-margin growth. The company's stage is commercial, indicating established revenue streams, though its private status limits transparency. Continued investment in R&D and expansion into regulated markets like the US or Europe could drive future value. Overall, Qingfeng Pharmaceutical is well-positioned in China's pharmaceutical landscape, with opportunities to scale through partnerships and product differentiation.

Upcoming Catalysts (preview)

• 2027Approval of a novel chemical entity (NCE) in China40% success
• Q4 2026Strategic licensing agreement for international distribution55% success
• 2027Expansion into biologics or complex generics30% success